Antiapoptotic BCL-2 proteins determine Sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma by Tutusaus, Anna et al.
Oncotarget16701www.oncotarget.com
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib 
resistance and BH3-mimetic efficacy in hepatocellular carcinoma
Anna Tutusaus1,2, Milica Stefanovic1, Loreto Boix3, Blanca Cucarull1,2, Aynara 
Zamora1, Laura Blasco1, Pablo García de Frutos1, Maria Reig3, Jose C. Fernandez-
Checa1,4,5, Montserrat Marí1, Anna Colell1, Jordi Bruix3 and Albert Morales1,3
1Department of Cell Death and Proliferation, IIBB-CSIC, IDIBAPS, Barcelona, Spain
2Departament de Biomedicina, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain
3Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clínic of Barcelona, University of Barcelona, CIBEREHD, IDIBAPS, 
Barcelona, Spain
4Liver Unit, Hospital Clinic, CIBEREHD, Barcelona, Spain
5Research Center for Alcoholic Liver and Pancreatic Diseases, Keck School of Medicine of the University of Southern California, 
Los Angeles, CA, USA
Correspondence to: Albert Morales, email: amorales@clinic.ub.es
Keywords: liver cancer; BCL-2 family proteins; BH3-mimetics; mitochondria/apoptosis; sorafenib
Abbreviations: HCC, hepatocellular carcinoma; MMP, mitochondrial membrane potential; MOMP, mitochondrial outer membrane 
permeabilization; ROS, reactive oxygen species; WT, wild type
Received: November 30, 2017    Accepted: February 26, 2018    Published: March 30, 2018
Copyright: Tutusaus et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), 
and regorafenib, novel second line treatment after sorafenib failure, have efficacy 
limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate 
in the response to tyrosine kinase inhibitors; however, their role in HCC therapy 
with sorafenib/regorafenib remains uncertain. BH3-mimetic ABT-263 (navitoclax) 
enhanced sorafenib activity, inducing cell death via a mitochondrial caspase-
dependent mechanism, after BCL-xL/BCL-2 inhibition. Sorafenib-resistant hepatoma 
cells (HepG2R and Hep3BR) exhibited altered mRNA expression of BCL-2 and other 
anti-apoptotic family members, such as MCL-1, priming drug-resistant cancer cells to 
death by BH3-mimetics. ABT-263 restored sorafenib efficacy in sorafenib-resistant 
cell lines and HCC mouse models. Moreover, in mice xenografts from patient-derived 
BCLC9 cells, better tumor response to sorafenib was associated to higher changes 
in the BCL-2 mRNA pattern. HCC non-treated patients displayed altered BCL-2, 
MCL-1 and BCL-xL mRNA levels respect to adjacent non-tumoral biopsies and an 
increased BCL-2/MCL-1 ratio, predictive of navitoclax efficacy. Moreover, regorafenib 
administration also modified the BCL-2/MCL-1 ratio and navitoclax sensitized 
hepatoma cells to regorafenib by a mitochondrial caspase-dependent mechanism. In 
conclusion, sorafenib/regorafenib response is determined by BCL-2 proteins, while 
increased BCL-2/MCL-1 ratio in HCC sensitizes drug resistant-tumors against ABT-263 
co-administration. Thus, changes in the BCL-2 profile, altered in HCC patients, could 
help to follow-up sorafenib efficacy, allowing patient selection for combined therapy 
with BH3-mimetics or early switch them to second line therapy.
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INTRODUCTION
Hepatocellular carcinoma (HCC), the most common 
liver cancer [1], is often diagnosed at an advanced stage 
with poor prognosis. Its expected incidence increases due 
to the growing prevalence of non-alcoholic fatty liver 
disease associated to obesity and metabolic syndrome [2]. 
Despite several key therapeutic advancements the sole 
systemic agents with survival benefit are the multikinase 
inhibitors sorafenib [3] and regorafenib [4]. Unfortunately, 
the activity of these drugs is limited by primary and 
acquired drug resistance mechanisms [5, 6]. Thus, there 
is need to develop additional therapeutic agents to further 
enhance the still limited survival of the patients. The 
mechanisms for sorafenib and regorafenib escape are 
not well known. The role of cell death-related pathways 
involving mitochondria is gaining interest as an alternative 
approach to target cancers where the dependence on 
specific driver mutations for survival is not established. 
In this sense, HCC is a tumor with a complex genetic 
background where clear druggable addictions have not 
been validated.
The BCL-2 family proteins control apoptosis at the 
mitochondria by regulating mitochondrial outer membrane 
permeabilization (MOMP) by multidomain proapoptotic 
BAX and BAK. MOMP results in the cytosolic release of 
proapoptotic mitochondrial intermembrane space proteins 
such as cytochrome c and smac/DIABLO, leading to 
caspase activation and rapid cell death [7, 8]. Given this 
pivotal role, MOMP is highly regulated, mostly by pro- 
and anti-apoptotic members of the BCL-2 protein family. 
Among them, some BH3-only proteins directly activate 
BAX and BAK, such as BID, BIM, and PUMA, while 
others inactivate the multidomain anti-apoptotic BCL-2, 
BCL-XL, and MCL-1, such as BAD and NOXA. Multiple 
insults favor the MOMP and change the delicate balance 
established between activators and repressors of BAX/
BAK homo-oligomerization, resulting in cell death or in 
the appearance of drug resistance. BCL-2 family proteins 
and the mitochondrial-dependent apoptotic program have 
been previously reported as main components of the 
sorafenib cytotoxicity in hepatoma cells [9–14]. MCL-
1 depletion and BAX mitochondrial translocation [9, 
11], BAD increase [12], BIM status [13], mitochondrial 
oxidative stress accumulation [11, 14], are frequently 
observed after sorafenib exposure. Increased BCL-2 
family members, particularly BCL-xL levels have been 
connected to HCC growth [15] and sorafenib-resistance 
[16], validating the mitochondrial pathway as highly 
relevant in sorafenib therapy for HCC. This link was 
further demonstrated by the increased antitumoral activity 
registered when combining the BH3-mimetic ABT-737 
with sorafenib [13, 17].
Specific BCL-2 profiles that sensitize or provide 
therapeutic resistance against particular chemotherapeutic 
agents have been recently identified [18–22]. Novel 
strategies, based on ectopic expression and genetic/
pharmacological repression of specific BCL-2 proteins 
[23, 24], “mito-prime” cancer cells against drug treatments 
[25]. However, neither a specific signature in BCL-2 
proteins has been associated to sorafenib response, nor 
mitochondrial “priming for death” defined after sorafenib 
exposure. Interestingly, several BH3-mimetics that interact 
with specific BCL-2 family proteins have been identified 
and studied in on-going clinical trials. Consequently, we 
aimed to evaluate the occurrence of BCL-2 addiction in 
the sorafenib resistance displayed by HCC tumors, and to 
determine whether BH3-mimetics could take advantage of 
this mitochondrial adaptation during sorafenib treatment.
RESULTS
ABT-263 potentiates sorafenib activity on 
hepatoma cell lines
Our previous work [11] prompted our interest in 
searching therapeutic strategies that benefit from sorafenib 
cytotoxic effects in mitochondria. Taking advantage of this 
mitochondrial sensitization, BH3-mimetics could interact 
with anti-apoptotic BCL-2 family members to increase 
sorafenib efficacy in hepatoma cells. Hep3B, HepG2 
and PLC5 cells were treated with navitoclax (ABT-263) 
a specific BCL-2 and BCL-xL inhibitor in clinical study 
and exposed to sorafenib to test their efficacy (Figure 
1A–1C). ABT-263 potentiated the cytotoxic sorafenib 
effect in all hepatoma cell lines tested (Figure 1A–1C). 
To verify that navitoclax was our best option, we tested 
other reported BH3-mimetics and, although all compounds 
increased cell death to some extent, ABT-263 was clearly 
more efficient in combination with sorafenib on hepatoma 
cells (Supplementary Figure 1). After three days exposure, 
Hep3B, HepG2 and PLC5 cells treated with navitoclax 
were visibly sensitized to sorafenib (Figure 1D–1F), 
reproducing in crystal violet assays the MTT findings. 
This combined activity, in line with previous observations 
[16, 26], evidenced that ABT-263 is a potent sensitizer for 
sorafenib action in HCC cell lines.
Since ABT-263 effect on sorafenib efficacy is 
expected due to its sequestration of intracellular BCL-
2 and BCL-xL, we analyzed the effect of separately 
targeting both proteins. First, the FDA-approved BCL-2 
inhibitor ABT-199, even when used at high doses (0.1-5 
μM), was unable to potentiate sorafenib activity in Hep3B 
cells (Figure 2A) or in HepG2 cells (Supplementary 
Figure 2). In contrast, the potent and selective BCL-xL 
inhibitor A-1155463 exhibited similar efficacy than the 
observed after navitoclax administration (Figure 2B). 
Supporting these observations, BCL-xL mRNA reduction 
(72±5% knockdown), via siRNA transfection in Hep3B 
cells, recapitulated the increased sorafenib effect induced 
by navitoclax (Figure 2C). However, BCL-2 reduction 
(64±10% knockdown) did not significantly sensitize 
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against sorafenib, while co-silencing BCL-2/BCL-xL was 
equally effective (not shown here).
Therefore, the well-known decrease of MCL-1 
induced by sorafenib [11, 16], combined to BCL-xL/BCL-
2 reduction by RNA silencing or ABT-263 treatment, could 
be enough to cause hepatoma cell death as previously 
reported [16, 26]. Confirming this hypothesis, MCL-1 
targeting was highly effective to kill Hep3B and HepG2 
cells exposed to ABT-263 (Figure 2D, E). In sum, these 
experiments illustrate the ability of individual changes in 
BCL-2 family proteins to modulate sorafenib efficacy in 
hepatoma cells.
BCL-2, MCL1 and BCL-xL mRNA levels are 
altered in tumoral tissue from HCC patients
At this point, it would be interesting to analyze in 
human biopsies BCL-2, MCL-1 or BCL-xL levels during 
follow-up to test their correlation with the tumor response 
under sorafenib. Unfortunately, sorafenib treatment 
is delivered to patients with advanced hepatocellular 
carcinoma that are not routinely biopsied just prior to 
treatment. To gain some insight into the expression 
pattern of BCL-2 family protein, we tested in untreated 
HCC samples (<5cm) without vascular invasion (I-
II TNM stage) from Ethanol/HCV cirrhotic patients 
(n=12) for mRNA changes respect to adjacent non-
tumoral biopsies (n=12) and to healthy livers (n=10), 
as detailed in Supplementary Figure 3. HCC biopsies 
exhibited enhanced BCL-2 and decreased MCL-1 levels 
compared to control livers (Figure 3A, B). In addition, 
some individuals exhibited increased BCL-xL levels 
in cirrhotic or tumoral areas (Figure 3C). The BCL-2/
MCL-1 ratio has been proposed as predictor of in vitro 
sensitivity to navitoclax in human myeloma cell lines [22]. 
Interestingly, a significant increase in BCL-2/MCL-1 was 
displayed by HCC samples, that was not presented by 
the neighboring cirrhotic tissue (Figure 3D), suggesting 
that this modification could be associated to tumor 
development.
BCL-2 protein alteration during sorafenib 
resistance renders hepatoma cells sensitive to 
ABT-263 administration
After long-time exposure to sorafenib, we analyzed 
in sorafenib-resistant HepG2 and Hep3B cells if mRNA 
changes in anti-apoptotic BCL-2 related proteins could be 
induced by sorafenib resistance, and provide clues about 
potential BH3-mimetic uses. A significant BCL-2 increase 
was observed in both resistant cell lines, respect to their 
parental cells (Figure 4A). Particularly, an enhanced BCL-
2/MCL-1 ratio (5.4±0.9 and 2.9±0.7, respectively) was 
detected. Minor changes in BCL-2/MCL-1 protein levels 
Figure 1: ABT-263 potentiated sorafenib cytotoxicity against different hepatoma cell lines.  (A-C) MTT assays to test ABT-
263 effect on sorafenib cytotoxicity in different liver cell lines (Hep3B, HepG2 and PLC5). (D-F) Crystal Violet staining was performed 
after 3 days exposure of sorafenib/ABT-263 in Hep3B, HepG2 and PLC5 cell cultures. (n=3) *P< 0.05 vs. control.
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were detected in HepG2 R and Hep3B R (2.2±0.4 and 
1.4±0.3) by western blot (Figure 4B), suggesting mRNA 
analysis as more sensitive indicator of anti-apoptotic BCL-
2 modifications in our samples.
In addition, changes in pro-apoptotic BCL-2 
family members were also detected in resistant cell lines. 
Particularly in Hep3B cells, an important alteration in 
several BCL-2-related mRNAs was caused by drug-
exposure. Analogous alterations in the BCL-2 network, 
recently observed in other cellular settings [23], have 
been postulated to create a BCL-2 addiction used by 
BH3-mimetics to eliminate tumor cells. In agreement, 
sorafenib-resistant cells Hep3B were sensitive to ABT-
263 alone (Figure 4C), while BCL-xL inhibitor A-1155463 
did not kill resistant hepatoma cells preferentially, as 
observed in Hep3B R (Figure 4D) and HepG2 R cells 
(Supplementary Figure 4).
Furthermore, navitoclax overcame sorafenib 
resistance in both hepatoma cell lines (Figure 4E, F), 
while BCL-2 inhibitor ABT-199 did not (Supplementary 
Figure 5). These results indicate that, although changes 
in BCL-xL have not been observed in HCC tumors or 
after sorafenib-exposure, basal BCL-xL levels should be 
playing an important role in hepatoma cells. Similarly 
sensitization by navitoclax was observed in crystal violet 
assays, underscoring the requirement for the simultaneous 
BCL-2/BCL-xL inhibition to counteract sorafenib-
resistance.
ABT-263 triggered mitochondrial-dependent 
apoptotic cell death after sorafenib exposure in 
hepatoma cell lines
ABT-263 is a potent BH3-mimetic that 
selectively inhibits BCL-xL and BCL-2. Thus, we 
expected that sorafenib-induced mitochondrial 
membrane permeabilization, and consequent release of 
intermembrane proteins such as cytochrome c, could be 
accelerated by ABT-263. Among main anti-apoptotic 
BCL-2 proteins, only MCL-1 was obviously affected by 
short-time sorafenib exposure, while no evident changes 
in BCL-2 or BCL-xL were detected (Figure 5A). In 
parallel, an increased in pro-apoptotic BIM levels was 
induced in sorafenib-treated samples, probably due to the 
minor phospho-BIM levels, and consequent proteosomal 
degradation, caused by sorafenib. Interestingly, PARP-1 
cleavage was early identified suggesting that ABT-263 
initiated cell death in sorafenib treated cells following 
MCL-1 levels depletion and BIM increase.
Similar to the timing of PARP-1 degradation, 
Hep3B cells pretreated with navitoclax exhibited a quick 
mitochondrial release of cytochrome c (Figure 5B), 
Figure 2: Sorafenib and ABT-263 activity on hepatoma cells depend on anti-apoptotic BCL-2 protein levels.  (A and 
B) Cell viability of Hep3B cells treated with specific inhibitors ABT-199 (BCL-2) and A-1155463 (BCL-xL) were tested in combination 
with sorafenib (μM). (C) Cell viability of Hep3B cells transfected with siRNAs control and against BCL-2 or BCL-xL, and treated with 
sorafenib. RNA interference was validated by qPCR. *P< 0.05 vs. control or siCTRL cells. (D and E) Hep3B and HepG2 cells were 
transfected with siRNAs control and against MCL-1 and treated and MTT assays performed after ABT-263 exposure. In parallel panels, 
protein levels of MCL-1 and β-actin are showed. (n=3) *P< 0.05 vs. control or siCTRL cells
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(Figure 5B) while no cytosolic increase in this apoptogenic 
protein was detected after 2-6 hours of sorafenib exposure. 
Similar patterns of cytochrome c and rapid PARP-1 
cleavage after ABT-263 incubation were observed in 
sorafenib-treated HepG2 and PLC5 cells, (Supplementary 
Figure 6). Incidentally, no additional reduction in 
mitochondrial membrane potential or ATP levels were 
noticed in sorafenib-treated cells after navitoclax 
administration (Supplementary Figure 7).
Sorafenib is an inducer of autophagy, which could 
preserve survival after cytochrome c release in the absence 
of caspase activation [27]. To verify that the MOMP was 
leading to apoptotic cell death by a caspase-dependent 
mechanism, we measured caspase-3 activity. A remarkable 
increase in caspase-3 activity was detected following 
ABT-263 addition to sorafenib-treated hepatoma cells 
(Figure 5C), paralleling the PARP proteolysis previously 
observed. Consistent with an apoptotic sequence of events, 
an evident nuclear condensation and fragmentation was 
visualized in sorafenib-treated cells incubated with 
navitoclax (Figure 5D). Of note, the pre-addition of a 
pancaspase inhibitor Z-VAD-FMK (z-VAK) significantly 
reduced the amount of apoptotic Hep3B cells (8.5±2.0 
vs. 24.5±4.1) counted after the ABT-263/sorafenib 
combination (Figure 5E).
Sorafenib modifies the BCL-2 system in HCC 
mouse models and benefits from ABT-263/
sorafenib co-administration
HepG2 cells were subcutaneously inoculated 
in nude mice and treated with sorafenib, ABT-263 or 
the combination of both drugs. HepG2 tumors treated 
with ABT-263/sorafenib exhibited minor tumor growth 
(Figure 6A) and increased cell death, as visualized by 
TUNEL staining (Figure 6B), and quantified (Figure 
Figure 3: Alterations in BCL-2, MCL-1 and BCL-xL mRNA levels in HCC patients. (A) BCL-2, (B) MCL-1, (C) BCL-
xL and (D) BCL-2/MCL-1 mRNA levels were measured by qPCR in healthy liver (n=10) and in cirrhotic and tumoral tissue from HCC 
patients (n=12) with HCV/EtOH etiology. *P< 0.05.
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6C). The anti-apoptotic BCL-2 protein system was 
analyzed in sorafenib-treated tumors. Enhanced 
mRNA levels of BCL-2 (3.0±0.8) and BCL-2/
MCL-1 (3.4±0.7) ratio compared to vehicle-tumors 
(Figure 6D) were detected; supporting that sorafenib 
exposure is triggering a BCL-2 profile alteration. 
Accordingly, when injecting sorafenib-resistant HepG2 
cell subcutaneously to mice, the tumors recovered 
Figure 4: Sorafenib-resistant hepatoma cells exhibit mRNA changes in BCL-2 proteins and are re-sensitized to 
sorafenib by ABT-263 exposure. (A) mRNAs levels of different BCL-2 family proteins from sorafenib sensitive (S) and sorafenib 
resistant (R) Hep3B and HepG2 cells. *P< 0.05 vs. sensitive hepatoma cells. (B) Representative western blot images of MCL-1, BCL-xL, 
BCL-2 and β-Actin protein levels exhibited by Hep3B and HepG2 sorafenib sensitive (S) and sorafenib resistant (R) cells. (C) Effect of 
ABT-263 in sensitive and sorafenib-resistant Hep3B cells. *P< 0.05 vs. sensitive cells. (D) Effect of A-1155463 exposure to sensitive and 
sorafenib-resistant Hep3B cells. (E-F) Effect of ABT-263 administration on sorafenib response in sorafenib-resistant Hep3B and HepG2 
cells, measured by MTT assay. *P< 0.05 vs. vehicle-treated cells. Representative Crystal violet staining images. (n=3).
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sensitivity to sorafenib exposure when the animals were 
gavaged simultaneously with sorafenib and ABT-263 
(Figure 6E, 6F). Neither sorafenib nor navitoclax alone 
(data not shown) reduced tumor growth.
Sorafenib alters the antiapoptotic BCL-2 profile 
predicting tumor response in vivo
To verify these observations we used the anchor-free 
growing human hepatocellular carcinoma cells. BCLC9 
cells, established from a well-differentiated human HCC, 
exhibit a stem cell phenotype and are highly efficient 
tumor initiating cells in nude mice [28]. Mimicking the 
results obtained in mice bearing HepG2 tumors, ABT-
263 was highly effective reducing the growth of BCLC9 
tumors treated with sorafenib (Figure 7A). No hepatic 
damage was caused, as denoted by lack of variations 
in serum ALT/AST levels (data not shown) and H&E 
staining of liver biopsies (Figure 7B).
Once again, an altered BCL-2 protein pattern was 
observed upon sorafenib exposure. Interestingly, when we 
analyzed the BCL-2/MCL-1 ratio, predictive value of the 
observed ABT-263 efficacy (Figure 7C), we distinguished 
a parallelism between tumor growth and BCL-2/MCL-
1 levels among sorafenib-only treated tumors (n=11). 
BCLC9 tumors more sensitive to sorafenib (green squares) 
displayed higher BCL-2/MCL-1 ratios compared to more 
resistant tumors (red squares) where sorafenib was less 
effective (Figure 7C). Sorafenib-treated BCLC9 tumors 
not only up-regulated anti-apoptotic BCL-2 proteins 
such as BCL-2 or BCL-w, but also increased other pro-
apoptotic BCL-2 members such as BIM, with higher 
values associated to better sorafenib response (Figure 7D). 
In addition, a good correlation was found between BCL-
2/MCL-1 expression and sorafenib-induced cytotoxicity 
(0.938, Pearson coefficient) in the hepatoma cell lines 
examined (Supplementary Figure 8), maybe supporting this 
ratio also as indicative of sorafenib efficacy.
Figure 5: Sorafenib/ABT-263 combination induced apoptotic cell death via a mitochondrial caspase-dependent 
mechanism. (A) Hep3B cells were exposed to sorafenib (S, 10 μM) with or without ABT-263 (A, 5 μM) and expression levels of indicated 
proteins were analyzed by Western blot, using β-actin as a loading control. (B) cytochrome c levels were analyzed by western blot in the 
cytosol of Hep3B cells at different times, and (C) fold increase in caspase-3 activity was determined in total cell extracts as above. (D-E) 
Nuclear Hoechst 33258 staining was visualized in Hep3B cells treated with sorafenib and/or ABT-263, and apoptotic positive cells counted 
in 10 independent fields per condition. (n=3) *P< 0.05 vs. control Hep3B cells.
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Figure 6: Sorafenib altered the mRNA BCL-2 pattern in vivo and ABT-263 increases sorafenib efficacy in murine 
subcutaneous HepG2 models. (A) Tumor growth in mice bearing HepG2-subcutaneous tumors that were given orally ABT-263 (100 
mg/kg) and/or sorafenib (80 mg/kg) daily for 3 weeks (CTRL, n=6; ABT, n=3; SOR, n=6; SOR+ABT, n=8). *P< 0.05 vs. vehicle-treated 
mice. (B-C) Representative images of tumor samples stained for TUNEL detection and graphic quantification. (D) Representation of anti-
apoptotic BCL-2 mRNAs levels in HepG2 tumors treated with vehicle or sorafenib. Subcutaneous tumor samples were obtained from mice 
gavaged with vehicle (CTRL) or sorafenib (SOR) daily for 3 weeks. *P< 0.05 vs. vehicle-treated tumors. (E-F) Representative images and 
tumor growth quantification of sorafenib-resistant HepG2 tumors in mice treated orally with sorafenib (80 mg/kg) and ABT-263 (100 mg/
kg) for 3 weeks (n=6). *P< 0.05 vs. vehicle-treated mice.
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Figure 7: ABT-263 potentiated sorafenib effectiveness in an experimental HCC model, being changes in the BCL-2 
profile indicative of sorafenib response.  (A) Tumor growth in mice bearing BCLC9-subcutaneous tumors that were daily gavaged 
with ABT-263 (100 mg/kg) and/or sorafenib (80 mg/kg) (CTRL, n=12; ABT, n=6; SOR, n=11; SOR+ABT, n=8). *P< 0.05 vs. vehicle-
treated mice. #P< 0.05 vs. sorafenib-treated mice. (B) Representative H&E liver images from vehicle and sorafenib/ABT-263 treated mice. 
(C) BCL-2/MCL-1 mRNA ratio of BCLC9 tumors treated with vehicle (CTRL) or sorafenib (SOR). Samples in green exhibited increased 
sorafenib efficacy, while tumors in red were less responsive (% respect to median growth). (D) Representation of mRNA changes in 
members of BCL-2 family exhibited by sensitive (S1 to S4) and resistant (R1 to R4) BCLC9 tumors following sorafenib administration. 
*P< 0.05, **P< 0.01 vs. vehicle-treated tumors. #P< 0.05, ##P< 0.01 vs. sorafenib-sensitive tumors. (E) mRNA levels of ASC, SOCS1, 
TLR4, CDH13 and FADD in tumors from mice treated with vehicle, sorafenib or sorafenib/ABT-263 (n=4). (F) Serum levels of human 
IL-1β in mice as above. *P< 0.05 vs. vehicle-treated mice.
Oncotarget16710www.oncotarget.com
Sorafenib-induced inflammation is reduced by 
navitoclax co-administration
Finally, we analyzed the modification of cellular 
pathways involved in liver cancer in sorafenib-
treated BCLC9 tumors using a gene array. When we 
focused on mRNAs presenting major upregulation 
following sorafenib exposure, we detected an increase 
in genes associated to inflammasome activation and 
inflammatory response such as TLR4 and ASC, among 
others (Figure 7E). As readout of inflammasome 
induction we checked for serum IL-1β levels in the 
treated animals. IL-1β was significantly increased 
in the serum of BCLC9-bearing mice treated with 
sorafenib (Figure 7F). This relationship inflammation/
tumor growth is consistent with the observation 
that inflammatory side effects related to sorafenib 
administration, such as dermatology hand-food-skin 
reaction, are associated to slower tumor growth and 
improved survival. Interestingly, ABT co-administration 
potentiated cell death and reduced tumor growth without 
additional inflammatory reaction. On the contrary, 
decreased IL-1β circulatory levels were exhibited by 
mice receiving sorafenib/ABT-263 suggesting the 
possibility of achieving increase sorafenib activity, not 
linked to enhanced inflammation.
Regorafenib modifies the BCL-2/MCL-1 ratio in 
hepatoma cells and ABT-263 co-addition induces 
mitochondrial caspase-dependent death
Since regorafenib has been approved as second 
line treatment for HCC progressing after sorafenib, we 
analyzed if navitoclax could also potentiate regorafenib 
activity. First, we measured mRNA changes in the BCL-
2/MCL-1 ratio. In HepG2 cells, regorafenib highly 
increased the BCL-2/MCL-1 levels after 10 hours 
(15.6±4.8 fold increase), while a 5.4±1.2 fold increase 
was observed in Hep3B cells. Consistently, ABT-263 
greatly sensitized HepG2 cells to regorafenib (Figure 8A), 
and had significant effects on Hep3B cells (Figure 8B). 
As soon as 4 hours after regorafenib exposure, MCL-1 
levels were reduced in HepG2 cells, probably due to an 
increase proteasomal degradation induced by regorafenib 
ERK inhibition [29], mechanism also relevant in sorafenib 
action as observed before. Moreover, ABT-263 co-
administration induced cytosolic cytochrome c released 
and PARP-1 cleavage (Figure 8C), and a moderate 
increased in BIM levels was detected. Similar effects 
were observed in Hep3B cells (data not shown), inducing 
obvious apoptotic features as denoted by caspase-3 
activity (Figure 8D), Hoechst staining (Figure 8E) and 
apoptotic cell counting (Figure 8F).
Figure 8: Regorafenib/ABT-263 combination induced apoptotic cell death via a mitochondrial caspase-dependent 
mechanism. (A-B) HepG2 and Hep3B cells were exposed to regorafenib/ABT-263 and MTT viability measured after 16 h. (C) cytochrome 
c levels were analyzed by western blot in the cytosol and BCL-xL, BIM, MCL-1 and PARP-1 in total extracts from hepatoma cells treated 
with regorafenib (5 μM) and/or ABT-263 (5 μM). (D) fold increase in caspase-3 activity was determined in total cell extracts as above. 
(E-F) Nuclear Hoechst 33258 staining was visualized in Hep3B cells treated with regorafenib and/or ABT-263, and apoptotic positive cells 
counted in 10 independent fields per condition. (n=3) *P< 0.05 vs. control cells.
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DISCUSSION
Sorafenib, drug recommended as first-line of 
treatment for HCC patients [3, 30], requires assistance 
to completely halt HCC progression. Although immune 
checkpoint inhibition could be helpful [31], so far less 
than 25% of HCC patients exhibit a molecular signature 
that could be linked to objective response to immune-
targeted therapy [32]. Therefore, we still need early 
markers of sorafenib efficacy or failure. Quantifying BCL-
2 family members in sorafenib HCC therapy, aligns with 
proposed determinations of mRNA and protein BCL-2 
profile [19–22, 33, 34] as indicative of treatment efficacy 
in colorectal cancer, lymphoid and myeloid leukemia, 
among others. Currently, profiling by tumor biopsy has no 
impact in HCC clinical decision-making and most patients 
are diagnosed by using imaging criteria [35]. Our work 
supports the analysis of BCL-2 family proteins in patients 
undergoing treatment, as potential tool to stratify them 
according to expected evolution under sorafenib.
The approval of regorafenib as second line drug after 
sorafenib treatment [4] underscores the clinical relevance 
of techniques to promptly switch patients from first line 
to second line therapy. Our in vitro data indicates that 
regorafenib also increases the BCL-2/MCL-1 ratio and 
ABT-263 administration is able to sensitize hepatoma cells 
against regorafenib. An altered BCL-2 pattern, present 
in HCC biopsies, may also be indicative of regorafenib 
response and of BH3-mimetics capacity to potentiate 
regorafenib activity. Besides immunotherapy, novel targets 
for sorafenib acquired resistance are proposed, such as 
Focal Adhesion Kinase [36], ceramide generation [11] 
or Metallothionein-1G [37]. In the absence of surrogate 
serum markers, biopsies of sorafenib-treated tumors will 
help to validate them, increasing our knowledge of HCC 
vulnerabilities.
Beyond the predictive value of BCL-2 profile 
in sorafenib/regorafenib efficacy, BH3 mimetics are 
interesting compounds in combination with sorafenib, 
since sorafenib resistance could be generating a targetable 
BCL-2 addiction (Figure 9). Most common mutations 
in HCC, such as p53 and beta-catenin, are undruggable. 
Therefore, new targetable proteins are required to improve 
HCC management. In this sense, several BH3 mimetics 
are already in clinical trials, and others, as BCL-xL 
inhibitors, are under scrutiny for cancer treatment as the 
biomedical importance of this pathway has been unveiled 
[38, 39]. Among them, venetoclax (ABT199) recently 
approved for leukemia therapy [40] and reported to cause 
minor side effects on treated patients appears highly 
promising [41]. Unfortunately, it does not seem to be 
effective in combination with sorafenib in HCC treatment 
Figure 9: Scheme representing the mitochondrial effects induced by sorafenib and BH3-mimetics on hepatoma cells. 
(I) Non-stimulated cells present expression of different BCL-2 family members. (II) After exposure to apoptotic stimuli that induce 
mitochondrial-dependent cell death, BH3-only apoptotic sensitizers, such as BIM or BID, if not sequestered by BCL-2 anti-apoptotic 
molecules, it will bind to and activate effector molecules BAX or BAK. This process leads to BAX/BAK oligomerization, mitochondrial 
membrane permeabilization, and the mitochondrial release of apoptogenic proteins such as cytochrome c. (III) Specific stimuli, like 
sorafenib, alter the levels of anti-apoptotic BCL-2 proteins avoiding cell death, but mito-priming the surviving cells to BH3-mimetics. (IV) 
In hepatoma cells after sorafenib exposure, ABT-263 sequesters anti-apoptotic BCL-2 and BCL-xL releasing BH3-only proteins such as 
BIM to bind BAX/BAK and trigger cell death.
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(Figure 2A and Supplementary Figure 3). Although BCL-
2/MCL-1 ratio could be an indicative marker of sorafenib 
activity, simultaneous BCL-xL inhibition seems to be 
required to potentiate sorafenib action. In agreement, 
navitoclax (ABT-263) is much more interesting, although 
the appearance of thrombocytopenia in patients has limited 
its development, particularly in hematologic malignancies 
[38]. In fact, an on-going clinical trial is testing the 
combination of navitoclax and sorafenib in HCC patients 
(NCT02143401), which would benefit from biomarkers 
for patient selection and follow up, such as the one we 
proposed.
Moreover, other BH3 mimetics could potentiate 
sorafenib effects. The lack of ABT-199 efficacy in 
combination with sorafenib, may suggest that HCC 
behaves as a BCL-xL-dependent tumor. So, BCL-xL 
inhibitors such as A-1155463 or A-133185 could deserve 
to be tested [35, 38, 39] in HCC treatment, despite not 
improving navitoclax effect in our models. As observed 
in patients, specific individuals exhibited remarkable 
differential expression of BCl-2 and BCL-xL that may 
justify different strategies in their treatments. Despite 
their similarities, BCL-2 and BCL-xL do not interact 
with the same proteins [39]. Both proteins are sensitized 
by increased BIM levels, as detected after sorafenib 
administration [42], but bind BAX and BAK differently. 
While all anti-apoptotic BCL-2 proteins bind BAX, only 
MCL-1 and BCL-xL bind BAK [43]. Coadministration of 
sorafenib and ABT-263 could unleash BAK from MCL-
1 and BCL-xL respectively [44], and sequester BCL-2 
from BAX, triggering simultaneously BAK activation 
and BAX translocation. Further studies could be necessary 
to assess this point, since complex interactions, and not 
simply expression patterns of BCL-2 proteins [45], may 
need to be investigated to optimize BH3-mimetics use and 
understand BCL-2 dependence. For instance, ABT-263 
not also binds BCL-2 and BCL-xL but also increases the 
protein and mRNA levels of other BLC-2 proteins such as 
MCL-1 [46], besides activating ERK and AKT. Precisely 
through this kinase activity, navitoclax may also have an 
induction role in BCL-2 [47] and BCL-xL [48] expression. 
These effects exerted by ABT-263, and probably by 
other BH3-mimetics, should also be kept in mind. 
Furthermore, both navitoclax and the A-1331852 BCL-
xL inhibitor induce apoptotic death in PDGF-activated 
hepatic fibroblast and in vivo reduce liver fibrosis in the 
MDR2-/- mouse model [49], supporting a link between 
BH3-induced apoptosis and liver fibrogenesis [50]. It is 
tempting to speculate that these features may become a 
second benefit in liver cancer patients with underlying 
chronic liver disease.
Finally, clinical practice associates a better outcome 
in sorafenib therapy to the development of adverse 
events such as hand-food-skin reaction. Chemotherapy 
frequently induces inflammasome components that 
contribute to the body pro-inflammatory response [51, 
52]. In particular, a relationship between dermatologic 
adverse events and complete response under sorafenib in 
patients with hepatocellular carcinoma has been recently 
established [53]. Probably related to this, sorafenib 
causes mitochondrial ROS production and a severe 
decline in mitochondrial membrane potential. Relevantly, 
recent reports associate inflammasome activation 
to mitochondrial injury [52–54] and inflammasome 
restriction to removal of damaged mitochondria [55]. 
Regarding this point, our data may not be sufficient 
to assess this complicated network, e.g. different 
inflammasomes, canonical vs. non-canonical activation. 
Yet, navitoclax effect on inflammasome induction and 
side-effects in patients are aspects that deserve further 
analysis.
In conclusion, the BCL-2 profile determines 
sorafenib/regorafenib response and could help to early 
stratify patients before and under treatment. Meanwhile, 
navitoclax in particular, and BH3-mimetics in general, 
reveal as an interesting sorafenib combination to overcome 




Dulbecco’s Modified Eagle’s Medium (DMEM), 
trypsin-EDTA, penicillin-streptomycin and dimethyl 
sulfoxide (DMSO), MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) (M2128), Hoechst 
33258 (B1155), Crystal Violet (C0755), and DCF (D6883) 
were purchased from Sigma-Aldrich (St. Louis, MO). All 
tissue culture-ware was from Nunc (Roskilde, Denmark). 
Biotin Blocking System, peroxidase substrate (DAB) and 
peroxidase buffer were from DAKO (Glostrup, Denmark). 
Aquatex was from Merck (Darmstadt, Germany). The 
ABC kit was from Vecstain (Burlingame, CA). Proteinase 
inhibitors were from Roche (Madrid, Spain). ECL western 
blotting substrate was from Pierce (Thermo Fisher 
Scientific, Rockford, IL). BCL-2 siRNA (h) (sc-29214), 
BCL-xL siRNA (h) (sc-43630), MCL-1 siRNA (h) (sc-
35877) and scrambled controls were purchased from Santa 
Cruz Biotechnology (Dallas, TX). Lipofectamine2000 
(11668-027), Novex Sharp Pre-stained Protein Standard 
(LC5800) and JC-1 (T-3168) were from Invitrogen Life 
Technologies (Carlsbad, CA). Sorafenib (BAY 43-9006, 
Nexavar) and Regorafenib (BAY 73-4506, Stivarga) are 
manufactured by Bayer. A-1155463, ABT-737, AT101, 
HA-14, ABT-263 (Navitoclax) and ABT-199 (Venetoclax) 
were purchased from Selleckchem (Houston, TX).
Cell culture and biochemical analysis
Human liver tumor cell lines Hep3B, PLC and 
HepG2 (European Collection of Animal Cell Cultures 
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(ECACC)) were grown in DMEM (10% FBS) at 37°C 
and 5% CO2. Sorafenib-resistant hepatoma cells [11], 
were maintained at 2.5 μM sorafenib and kept without 
drug at least one week before experiments. Cell viability 
measured by MTT assay and clonogenic assays by Crystal 
Violet Staining, Hoechst staining, and caspase-3 activity 
were analyzed as previously indicated [11, 56].
Immunoblot analysis
Cell lysates were prepared in RIPA buffer plus 
proteinase inhibitors. Samples containing 10 to 30 μg 
were separated by 10-15% SDS-PAGE. Proteins were 
transferred to nitrocellulose membranes, blocked in 5% 
nonfat milk for 1h at room temperature, and incubated 
overnight at 4°C with the primary antibodies:
MCL-1 (S-19) (SantaCruz, sc-819) 1:250 rabbit
BCL-2 (C-2) (SantaCruz, sc-7382) 1:250 mouse
BCL-xL (H-5) (SantaCruz, sc-8392) 1:250 mouse
PARP-1 (H-250) (SantaCruz, sc-7150) 1:250 rabbit
BIM (H-191) (SantaCruz, sc-11425) 1:250 rabbit
 Phospho-BIM (Ser69) (Cell Signaling, #4581) 
1:1000 rabbit
 Cytochrome C (SantaCruz, sc-1356) 1:250 mouse
 β-Actin (Sigma-Aldrich, A3854) 1:40,000 
conjugated to HRP
RNA isolation and real time RT-PCR
Total RNA was isolated with TRIzol reagent. 1ug 
of RNA was reverse-transcribed with iScript™ cDNA 
Synthesis Kit (Biorad, Berkeley, CA) and real-time 
PCR was performed with iTaq™ Universal SYBR® 
Green Supermix (Biorad, Berkeley, CA) following 
the manufacturer’s instructions [11, 56]. The primers 
sequences used were:
human BCL-2: Fw 5’-GGAGGATTGTGGCCTTCTTT-3’
  Rv 5’-GCCGTACAGTTCCACAAAGG-3’
human BCL-xL: Fw 5’-GGATGGCCACTTACCTGA-3’
  Rv 5’-CGGTTGAAGCGTTCCTG-3’
human MCL-1: Fw 5’-ATGCTTCGGAAACTGGACAT-3’
  Rv 5’-TCCTGATGCCACCTTCTAGG-3’
human BCL-B: Fw 5’-GCTGGGATGGCTTTTGTCA-3’
  Rv 5’-GCCTGGACCAGCTGTTTTCTC-3’
human BCL-w: Fw 5’-ACCCCAGGCTCAGCCCAACA-3’
  Rv 5’-CAGCACACAGTGCAGCCCCA-3’
human BFL-1: Fw 5’-TTACAGGCTGGCTCAGGACT-3’
  Rv 5’-AGCACTCTGGACGTTTTGCT-3’
human BIM: Fw 5’-TGGCAAAGCAACCTTCTGATG-3’
  Rv 5’-GCAGGCTGCAATTGTCTACCT-3’
human NOXA: Fw 5’-TGGAAGTCGAGTGTGCTACTCA-3’
  Rv 5’-CAGAAGAGTTTGGATATCAGATT-3’
human PUMA: Fw 5’-GCATGCCTGCCTCACCTT-3’
  Rv 5’-TCACACGTCGCTCTCTCTAAACC-3’
human β-Actin: Fw 5’-AGAAAATCTGGCACCACACC-3’
  Rv 5’-AGAGGCGTACAGGGATAGCA-3’
human 18S: Fw 5’-CCGAAGATATGCTCATGTGG-3’
  Rv 5’-TCTTGTACTGGCGTGGATTC-3’
Immunohistochemical staining
Liver and tumor samples were fixed and 5-μm 
sections were prepared following standard procedures. 
The slices were examined with a Zeiss Axioplan 
microscope equipped with a Nikon DXM1200F digital 
camera. Apoptotic cells with fragmented nuclei were 
detected in paraffin samples using TUNEL labeling 
containing fluorescein-dUTP and -dNTPs (TUNEL Label 
Mix, Roche). TUNEL positive cells were observed and 
quantified using a NIKON Eclipse E-100 microscope.
Tumor animal models
All animal procedures were performed according 
to protocols approved by the Animal Experimentation 
Ethics Committee from the University of Barcelona. 
For subcutaneous tumor model, male Swiss nude mice, 
5-6 week old, were kept under pathogen-free conditions 
with free access to standard food and water. HepG2 
cells (5×106) or BCLC9 cells (2.5×106) were injected 
subcutaneously into the flanks of mice in 100 μL DMEM 
without FBS, as previously reported [11, 57]. Treatments 
with ABT-263 (100 mg/Kg body weight), sorafenib (80 
mg/Kg) or vehicle (12.5% Cremophor, 12.5% ethanol, 
75% sterile saline) were delivered daily via oral gavage 
for 21 days. Tumors were measured periodically with a 
Vernier caliper, and the volume was calculated as length 
× width2 × 0.5.
Gene array
A predesigned 384-well human Liver cancer panel 
(SAB Target List, H384 Cat#10034526) for SYBR Green 
detection (Bio-rad) was used following the manufacturer’s 
instructions, as previously reported [56].
HCC patient study
Samples, tumor and non-tumor biopsies, from 
twelve patients diagnosed with HCC and treated at the 
Clinic Hospital in Barcelona, and ten healthy liver samples 
from patients subjected to surgery due to colorectal cancer 
without any diagnosed liver disease, were included. 
Patients gave informed consent in according to the 
principles embodied in the Declaration of Helsinki.
Statistical analyses
Results are expressed as mean ± standard deviation 
and n=3, unless indicated. Statistical comparisons were 
usually performed using unpaired 2-tailed Student’s t test, 
and 1-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test (GraphPad Prism) was used for data 
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quantification from patients. A P value less than 0.05 was 
considered significant.
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